Idiopathic Environmental Intolerance (IEI) denotes a functional disorder represented by heterogeneous symptoms that sufferers attribute to specific environmental agents and for which there may be no solid evidence of an underlying physiological cause. We are conducting a randomized controlled trial study to compare patients before and after a newly developed cognitive behavioral therapy treatment program for IEI, with respect to behavioral and psychometric variables. The results of this research project are expected to contribute to advancements in the clinical treatment of IEI, as well as to elaborate on existing theoretical models of IEI.
Introduction: A percentage of the population report various, nonspecific somatic and cognitive symptoms (e.g., headaches, nausea, fatigue, difficulty concentrating...) that they causally attribute to agents in their environments (chemicals, electromagnetic fields, windmills..). This condition is called Idiopathic Environmental Intolerance (IEI). It is proposed that the attribution of symptoms to an environmental agent, and the associated negative expectations is what drives symptom experience. We hypothesize that this, alongside other cognitive biases, are involved in the emergence and maintenance of symptoms. Treatment models have been developed, but no cognitive behavioral therapy was tested on IEI patients. The planned study aims to investigate the feasibility and efficacy of a cognitive behavioral treatment online program, in ameliorating quality of life in a French population of patients suffering from IEI. Methods and analysis: This parallel two-armed, randomized controlled trial, evaluates an 8-week guided intervention against a wait-list control group. It is a hybrid intervention that will include web-based consecutive modules based on disorder-specific cognitive behavioral therapy (CBT) as well as general transdiagnostic principles . Guidance will be provided by trained psychologists with weekly supportive feedback. As part of the "BELIEF" project, the present study aims to recruit n=82 patients indicating symptom attributed to factors in the environment. Assessments will take place at baseline and after intervention completion (12 and 24 weeks after randomization). The primary outcome will be measured by the SF-12 scale for quality of life. Secondary outcomes include symptom perception, severity and distress, eco-anxiety, emotional processing, intolerance to uncertainty and associated mental disorders such as depression and anxiety. Consumption of healthcare services will also be measured. Ethics and dissemination: Ethics approval has been granted. Results from this study will be published in peer-reviewed journals and presented at international conferences. Trial registration number: DRKS00014375
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
82
CBT for IEI
Unité de pathologies professionnelles et environnementales, Hôtel-Dieu
Paris, Paris, France
RECRUITINGShort Form Health Survey - 12
Measures quality of life with a minimum value of zero and a maximum value of 100. Higher score indicates better outcome.
Time frame: T0; 3 Months ; 6 Months
The Somatic Symptom Disorder - B Criteria Scale
Measures criteria for Somatic Symptom Disorder (SSD) and symptoms' burden: The total score ranges between 0 and 48, with a higher score reflecting higher levels of the psychological features of the SSD, or worse outcome.
Time frame: T0; 3 Months ; 6 Months
Symptom Interpretation Questionnaire
Measures causal attributions individuals make of common somatic symptoms by using three sub scales: somatic (range 13-36), psychological (range: 13-52), and environmental/normalizing (range: 17-49). Each sub score represents the extent with which each sub scale is endorsed as a possible cause for symptoms (higher score means higher outcome).
Time frame: T0; 3 Months ; 6 Months
QEESI (Quick environnemental exposure and sensitivity inventory)
Measures Chemical Sensitivity with 5 subscales: Symptoms, Chemical Intolerances, Other Intolerances, Masking, and Life Impact. Patients with no intolerance to chemicals only complete the subscales on Symptoms.
Time frame: T0; 3 Months ; 6 Months
11-item Electromagnetic Field Sensitivity Scale
Measures sensitivity to Electromagnetic Fields. The score can range from 0 to 54 (high score representing high annoyance/intolerance and worse outcome). Only patients reporting intolerance to Electromagnetic fields complete this questionnaire.
Time frame: T0; 3 Months ; 6 Months
Modern Health Worries Scale short (12-item) version
Measures Modern Health Worries (concerns of respondents about modern environmental issues). Scores range from 12 to 60 with higher scores indicating more concern or worse outcome.
Time frame: T0; 3 Months ; 6 Months
Climate Change Anxiety Scale
Measures Climate Change Anxiety with scores ranging from 13 to 65 and higher scores indicating higher levels of climate change anxiety, or worse outcome.
Time frame: T0; 3 Months ; 6 Months
Hospital Anxiety and Depression scale
Measures Depression and Anxiety. Score ranges from 0 to 21 with higher score representing worse outcome.
Time frame: T0; 3 Months ; 6 Months
Short version of the Intolerance of Uncertainty Scale
Measures Intolerance to Uncertainty with total scores ranging from 12 to 60 with higher score representing worse outcome. The total scores encompasses two sub-scales: prospective anxiety and inhibitory anxiety. A greater score in each subscale indicates a greater level of prospective anxiety and inhibitory anxiety.
Time frame: T0; 3 Months ; 6 Months
Body Perception Questionnaire - Very Short Form
Measures body awareness and autonomic stress response patterns. Scores range from 12 to 60. Particularly high scores may indicate the autonomic nervous system is frequently activated by stress or chronic threat responses (i.e. worse outcome)
Time frame: T0; 3 Months ; 6 Months
Levels of Emotional Awareness Scale 10 item
Measures the Level of Emotional Awareness with a maximum score of 50. Higher scores indicating greater awareness and differentiation in emotions, or better outcome.
Time frame: T0; 3 Months ; 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.